The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).
Percutaneous coronary intervention (PCI) is a standard treatment for significantly stenotic lesion of coronary arteries, especially in the setting of acute myocardial infarction (AMI) where timely reperfusion is important. Traditionally, visual assessment by coronary angiography has been the main tool to identify coronary artery disease and guide revascularization. However, it is known that angiography alone is unable to adequately evaluate significance of stenotic lesion or optimization status of the stent, and that angiography suffers from high intra- and interobserver variability. Thus, methods for intracoronary imaging and/or physiology have been developed to aid these limitations. During the PCI procedure, intravascular imaging devices such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on lesion characteristics and optimal stent implantation with regard to appropriate reference segment, stent expansion, stent apposition, and possible acute complications. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the randomized controlled trials were limited with small sample size and dealt with very selected lesion subsets such as chronic total occlusion (CTO) or long lesions. Moreover, although some studies observed similar clinical outcomes between IVUS-guided PCI and OCT-guided PCI, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI. Currently, randomized controlled trial to support beneficial impact of OCT-guided PCI, especially in patients with acute myocardial infarction (AMI) is lacking. One randomized clinical trial in 2016 with 240 non-ST-elevation myocardial infarction patients have reported higher postprocedural fractional flow reserve and similar incidence of major adverse cardiac events with the use of OCT compared to angiography alone, but this study mostly focused on immediate physiologic findings of OCT-guided PCI and only demonstrated clinical outcomes on short-term follow-up. Although the ILUMIEN IV trial evaluated efficacy of OCT-guided PCI among high risk patients including lesions were considered to be responsible for a recent myocardial infarction, there was no apparent difference in the target-vessel failure at 2 years. There is no randomized controlled trial that can provide information on its long-term clinical impact, and current clinical guidelines puts OCT on Class 2a recommendation as an alternative for IVUS, with the exception of ostial left main disease. In this regard, randomized controlled trial comparing clinical outcome following PCI in patients with AMI where procedural optimization is performed under OCT-guidance or angiography alone would provide valuable evidence to enhance prognosis after treatment of AMI. Therefore, FRAME-AMI 3 trial has been designed to compare clinical outcomes after PCI for infarct-related artery using either OCT-guided or angiography-guided strategy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
1,500
The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
\[Stent Optimization\] 1. Stent Expansion: Visually assess residual angiographic diameter stenosis \<10% "AND" ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area "OR" \>4.5 mm2 ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM 2. Stent Apposition: No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall 3. Edge Dissection: No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)
Dong-A University College of Medicine
Busan, South Korea
Target vessel failure
a composite of cardiac death, target-vessel myocardial infarction, clinically-driven target-vessel repeat revascularization, definite or probable stent thrombosis
Time frame: 2 years after last patient enrollment
All-cause death
All-cause death
Time frame: 2 years after last patient enrollment
Cardiac death
Cardiac death
Time frame: 2 years after last patient enrollment
Rate of any myocardial infarction
Any myocardial infarction, defined by Forth Universal definition of myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of spontaneous myocardial infarction
Spontaneous myocardial infarction, defined by Forth Universal definition of myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of procedure-related myocardial infarction
Procedure-related myocardial infarction, defined by ARC II definition
Time frame: 2 years after last patient enrollment
Rate of any revascularization
Any revascularization (clinically-driven or ischemia-driven)
Time frame: 2 years after last patient enrollment
Rate of target vessel revascularization
Target vessel revascularization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Kosin University Gospel Hospital
Busan, South Korea
RECRUITINGKyungpook National University Hospital
Daegu, South Korea
RECRUITINGYeungnam University Medical Center
Daegu, South Korea
RECRUITINGDaegu Catholic University Medical Center
Daegu, South Korea
RECRUITINGChonnam National University
Gwangju, South Korea
RECRUITINGWonkwang University Hospital
Iksan, South Korea
RECRUITINGInternational St. Mary's Hospital
Incheon, South Korea
RECRUITINGJeju National University Hospital
Jeju City, South Korea
RECRUITINGJeonbuk National University Hospital
Jeonju, South Korea
RECRUITING...and 11 more locations
Time frame: 2 years after last patient enrollment
Rate of stent thrombosis
Definite or probable stent thrombosis, defined by ARC II definition
Time frame: 2 years after last patient enrollment
Total procedural time
Total procedural time (primary PCI to end of the procedure including amount of staged procedure)
Time frame: at least 1 week after index procedure
Total fluoroscopy time
Total fluoroscopy time (primary PCI to end of the procedure including amount of staged procedure)
Time frame: at least 1 week after index procedure
Total amount of contrast use
Total amount of contrast use (primary PCI to end of the procedure including amount of staged procedure)
Time frame: at least 1 week after index procedure
Incidence of contrast-induced nephropathy
Incidence of contrast-induced nephropathy, defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure.
Time frame: at least 1 week after index procedure